Envestnet Asset Management Inc Prothena Corp Public LTD CO Transaction History

Envestnet Asset Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$12.7 - $15.79 $673 - $836	-53 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$27.95 - $45.04 $1,537 - $2,477	-55 Reduced 50.93%	53 $1,000
Q4 2017 Feb 20, 2018	SELL	$35.44 - $63.76 $1,913 - $3,443	-54 Reduced 33.33%	108 $4,000
Q2 2017 Aug 14, 2017	BUY	N/A	162	162 $8,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $678M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.